We are investigating Solid Biosciences Inc. (SLDB) (“Solid Biosciences” or the “Company”) for potential violations of the federal securities laws. On November 12, 2019, Solid Biosciences disclosed that the U.S. Food and Drug Administration (“FDA”) had placed the Company’s Ignite DMD Phase I/II clinical trial evaluating gene therapy candidate SGT-001 in Duchene muscular dystrophy on clinical hold as the result of a serious adverse event related to the study drug. On this news, Solid Biosciences’ stock price fell $8.18 per share, or 74.36%, to close at $2.82 per share on November 12, 2019. Then, on July 27, 2020, Solid Biosciences announced that the FDA had notified the Company on July 24, 2020 that the agency was maintaining the clinical hold and requested “further manufacturing information, updated safety and efficacy data for all patients dosed, and providing direction on total viral load to be administered per patient.” On this news, Solid Biosciences’ stock price fell $0.30 per share, or 10.53%, to close at $2.55 per share on July 27, 2020.